Understanding TLR9 action in epstein-barr virus infection

Frontiers in Bioscience

Volumn 17, Issue 4, 2012, Pages 1219-1231

  Zauner, Ludwig ^a,b   Nadal, David ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

B cell; Burkitt's lymphoma; Epstein barr virus; Malaria; Review; TLR9; Toll like receptor

Indexed keywords

BACTERIA (MICROORGANISMS); HUMAN HERPESVIRUS 4; PLASMODIUM FALCIPARUM;

TLR9 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 9;

EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; ISOLATION AND PURIFICATION; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; TOLL-LIKE RECEPTOR 9;

EID: 84859221717     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3982     Document Type: Article

References (109)

1. S. H. Speck and D. Ganem: Viral latency and its regulation: lessons from the gamma-herpesviruses. Cell Host Microbe, 8, 100-15 (2010).
2. L. S. Young and A. B. Rickinson: Epstein-Barr virus: 40 years on. Nat Rev Cancer, 4, 757-68 (2004). (Pubitemid 39331148)
3. S. A. Rezk and L. M. Weiss: Epstein-Barr virusassociated lymphoproliferative disorders. Hum Pathol, 38, 1293-304 (2007).
4. K. M. Shah and L. S. Young: Epstein-Barr virus and carcinogenesis: beyond Burkitt's lymphoma. Clin Microbiol Infect, 15, 982-8 (2009).
5. J. D. Lunemann, T. Kamradt, R. Martin and C. Munz: Epstein-Barr virus: environmental trigger of multiple sclerosis? J Virol, 81, 6777-84 (2007). (Pubitemid 46986614)
6. D. A. Thorley-Lawson and A. Gross: Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med, 350, 1328-37 (2004). (Pubitemid 38375368)
7. A. D. Hislop, G. S. Taylor, D. Sauce and A. B. Rickinson: Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol, 25, 587-617 (2007). (Pubitemid 46697918)
8. S. R. Paludan, A. G. Bowie, K. A. Horan and K. A. Fitzgerald: Recognition of herpesviruses by the innate immune system. Nat Rev Immunol, 11, 143-54 (2011).
9. L. M. Hutt-Fletcher: Epstein-Barr virus entry. J Virol, 81, 7825-32 (2007). (Pubitemid 47101468)
10. S. M. Tugizov, J. W. Berline and J. M. Palefsky: Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med, 9, 307-14 (2003). (Pubitemid 36362786)
11. S. H. Speck: EBV framed in Burkitt lymphoma. Nat Med, 8, 1086-7 (2002). (Pubitemid 35175962)
12. G. Kelly, A. Bell and A. Rickinson: Epstein-Barr virusassociated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med, 8, 1098-104 (2002). (Pubitemid 35175964)
13. D. A. Thorley-Lawson: Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol, 1, 75-82 (2001). (Pubitemid 33741978)
14. T. A. Souza, B. D. Stollar, J. L. Sullivan, K. Luzuriaga and D. A. Thorley-Lawson: Influence of EBV on the peripheral blood memory B cell compartment. J Immunol, 179, 3153-60 (2007).
15. S. Chaganti, E. M. Heath, W. Bergler, M. Kuo, M. Buettner, G. Niedobitek, A. B. Rickinson and A. I. Bell: Epstein-Barr virus colonization of tonsillar and peripheral blood B-cell subsets in primary infection and persistence. Blood, 113, 6372-81 (2009).
16. B. Ehlin-Henriksson, J. Gordon and G. Klein: Blymphocyte subpopulations are equally susceptible to Epstein-Barr virus infection, irrespective of immunoglobulin isotype expression. Immunology, 108, 427-30 (2003). (Pubitemid 36469679)
17. M. Dorner, F. Zucol, C. Berger, R. Byland, G. T. Melroe, M. Bernasconi, R. F. Speck and D. Nadal: Distinct ex vivo susceptibility of B-cell subsets to epstein-barr virus infection according to differentiation status and tissue origin. J Virol, 82, 4400-12 (2008). (Pubitemid 351563676)
18. M. Dorner, F. Zucol, D. Alessi, S. K. Haerle, W. Bossart, M. Weber, R. Byland, M. Bernasconi, C. Berger, S. Tugizov, R. F. Speck and D. Nadal: beta1 integrin expression increases susceptibility of memory B cells to Epstein-Barr virus infection. J Virol, 84, 6667-77 (2010).
19. W. Amon and P. J. Farrell: Reactivation of Epstein- Barr virus from latency. Rev Med Virol, 15, 149-56 (2005). (Pubitemid 40675906)
20. L. L. Laichalk and D. A. Thorley-Lawson: Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol, 79, 1296-307 (2005). (Pubitemid 40053911)
21. T. Tsurumi, M. Fujita and A. Kudoh: Latent and lytic Epstein-Barr virus replication strategies. Rev Med Virol, 15, 3-15 (2005). (Pubitemid 40070039)
22. M. Hug, M. Dorner, F. Z. Frohlich, C. Gysin, D. Neuhaus, D. Nadal and C. Berger: Pediatric Epstein-Barr virus carriers with or without tonsillar enlargement may substantially contribute to spreading of the virus. J Infect Dis, 202, 1192-9 (2010).
23. V. Hadinoto, M. Shapiro, C. C. Sun and D. A. Thorley- Lawson: The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog, 5, e1000496 (2009).
24. E. Bourke, D. Bosisio, J. Golay, N. Polentarutti and A. Mantovani: The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood, 102, 956-63 (2003). (Pubitemid 36917790)
25. N. L. Bernasconi, N. Onai and A. Lanzavecchia: A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood, 101, 4500-4 (2003). (Pubitemid 36857820)
26. V. Hornung, S. Rothenfusser, S. Britsch, A. Krug, B. Jahrsdorfer, T. Giese, S. Endres and G. Hartmann: Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol, 168, 4531-7 (2002). (Pubitemid 34441357)
27. I. Bekeredjian-Ding and G. Jego: Toll-like receptors-sentries in the B-cell response. Immunology, 128, 311-23 (2009).
28. M. Dorner, S. Brandt, M. Tinguely, F. Zucol, J. P. Bourquin, L. Zauner, C. Berger, M. Bernasconi, R. F. Speck and D. Nadal: Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology, 128, 573-9 (2009).
29. D. Chiron, I. Bekeredjian-Ding, C. Pellat-Deceunynck, R. Bataille and G. Jego: Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood, 112, 2205-13 (2008).
30. A. Mansson, M. Adner, U. Hockerfelt and L. O. Cardell: A distinct Toll-like receptor repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 and CpG-2006 stimulation. Immunology, 118, 539-48 (2006). (Pubitemid 44079572)
31. A. Iwasaki and R. Medzhitov: Toll-like receptor control of the adaptive immune responses. Nat Immunol, 5, 987-95 (2004). (Pubitemid 41057715)
32. Y. J. Liu: IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol, 23, 275-306 (2005).
33. A. M. Krieg: Development of TLR9 agonists for cancer therapy. J Clin Invest, 117, 1184-94 (2007). (Pubitemid 46718403)
34. M. Rutz, J. Metzger, T. Gellert, P. Luppa, G. B. Lipford, H. Wagner and S. Bauer: Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pHdependent manner. Eur J Immunol, 34, 2541-50 (2004). (Pubitemid 39302811)
35. A. Aderem and R. J. Ulevitch: Toll-like receptors in the induction of the innate immune response. Nature, 406, 782-7 (2000).
36. R. Medzhitov: Toll-like receptors and innate immunity. Nat Rev Immunol, 1, 135-45 (2001). (Pubitemid 33741967)
37. Y. Kumagai, O. Takeuchi and S. Akira: TLR9 as a key receptor for the recognition of DNA. Adv Drug Deliv Rev, 60, 795-804 (2008).
38. S. Ning: Innate immune modulation in EBV infection. Herpesviridae, 2, 1 (2011).
39. E. Gaudreault, S. Fiola, M. Olivier and J. Gosselin: Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2. J Virol, 81, 8016-24 (2007). (Pubitemid 47101487)
40. M. E. Ariza, R. Glaser, P. T. Kaumaya, C. Jones and M. V. Williams: The EBV-encoded dUTPase activates NF-kappa B through the TLR2 and MyD88-dependent signaling pathway. J Immunol, 182, 851-9 (2009).
41. D. Iwakiri, L. Zhou, M. Samanta, M. Matsumoto, T. Ebihara, T. Seya, S. Imai, M. Fujieda, K. Kawa and K. Takada: Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp Med, 206, 2091-9 (2009).
42. M. Samanta, D. Iwakiri, T. Kanda, T. Imaizumi and K. Takada: EB virus-encoded RNAs are recognized by RIG-I and activate signaling to induce type I IFN. EMBO J, 25, 4207-14 (2006). (Pubitemid 44435218)
43. A. Ablasser, F. Bauernfeind, G. Hartmann, E. Latz, K. A. Fitzgerald and V. Hornung: RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase IIItranscribed RNA intermediate. Nat Immunol, 10, 1065-72 (2009).
44. W. H. Lim, S. Kireta, G. R. Russ and P. T. Coates: Human plasmacytoid dendritic cells regulate immune responses to Epstein-Barr virus (EBV) infection and delay EBV-related mortality in humanized NOD-SCID mice. Blood, 109, 1043- 50 (2007). (Pubitemid 46220650)
45. S. Fiola, D. Gosselin, K. Takada and J. Gosselin: TLR9 contributes to the recognition of EBV by primary monocytes and plasmacytoid dendritic cells. J Immunol, 185, 3620-31 (2010).
46. S. Guggemoos, D. Hangel, S. Hamm, A. Heit, S. Bauer and H. Adler: TLR9 contributes to antiviral immunity during gammaherpesvirus infection. J Immunol, 180, 438-43 (2008).
47. C. Coban, K. J. Ishii, T. Kawai, H. Hemmi, S. Sato, S. Uematsu, M. Yamamoto, O. Takeuchi, S. Itagaki, N. Kumar, T. Horii and S. Akira: Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J Exp Med, 201, 19-25 (2005). (Pubitemid 40130079)
48. P. Parroche, F. N. Lauw, N. Goutagny, E. Latz, B. G. Monks, A. Visintin, K. A. Halmen, M. Lamphier, M. Olivier, D. C. Bartholomeu, R. T. Gazzinelli and D. T. Golenbock: Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc Natl Acad Sci USA, 104, 1919-24 (2007). (Pubitemid 46239879)
49. L. Zauner, G. T. Melroe, J. A. Sigrist, M. P. Rechsteiner, M. Dorner, M. Arnold, C. Berger, M. Bernasconi, B. W. Schaefer, R. F. Speck and D. Nadal: TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification. Oncogene, 29, 4588-98 (2010).
50. R. Rochford, M. J. Cannon and A. M. Moormann: Endemic Burkitt's lymphoma: a polymicrobial disease? Nat Rev Microbiol, 3, 182-7 (2005). (Pubitemid 40207598)
51. K. Heeg, A. Dalpke, M. Peter and S. Zimmermann: Structural requirements for uptake and recognition of CpG oligonucleotides. Int J Med Microbiol, 298, 33-8 (2008). (Pubitemid 350216551)
52. H. Hemmi, O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda and S. Akira: A Toll-like receptor recognizes bacterial DNA. Nature, 408, 740-5 (2000). (Pubitemid 32015992)
53. S. Bauer, C. J. Kirschning, H. Hacker, V. Redecke, S. Hausmann, S. Akira, H. Wagner and G. B. Lipford: Human TLR9 confers responsiveness to bacterial DNA via speciesspecific CpG motif recognition. Proc Natl Acad Sci USA, 98, 9237-42 (2001). (Pubitemid 32743900)
54. D. Verthelyi and R. A. Zeuner: Differential signaling by CpG DNA in DCs and B cells: not just TLR9. Trends Immunol, 24, 519-22 (2003). (Pubitemid 37205200)
55. T. Haas, J. Metzger, F. Schmitz, A. Heit, T. Muller, E. Latz and H. Wagner: The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation. Immunity, 28, 315-23 (2008). (Pubitemid 351335308)
56. K. Yasuda, C. Richez, M. B. Uccellini, R. J. Richards, R. G. Bonegio, S. Akira, M. Monestier, R. B. Corley, G. A. Viglianti, A. Marshak-Rothstein and I. R. Rifkin: Requirement for DNA CpG content in TLR9-dependent dendritic cell activation induced by DNA-containing immune complexes. J Immunol, 183, 3109-17 (2009).
57. G. M. Barton, J. C. Kagan and R. Medzhitov: Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol, 7, 49-56 (2006). (Pubitemid 41823868)
58. G. M. Barton and J. C. Kagan: A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol, 9, 535-42 (2009).
59. J. Tian, A. M. Avalos, S. Y. Mao, B. Chen, K. Senthil, H. Wu, P. Parroche, S. Drabic, D. Golenbock, C. Sirois, J. Hua, L. L. An, L. Audoly, G. La Rosa, A. Bierhaus, P. Naworth, A. Marshak-Rothstein, M. K. Crow, K. A. Fitzgerald, E. Latz, P. A. Kiener and A. J. Coyle: Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol, 8, 487-96 (2007). (Pubitemid 46605917)
60. S. Ivanov, A. M. Dragoi, X. Wang, C. Dallacosta, J. Louten, G. Musco, G. Sitia, G. S. Yap, Y. Wan, C. A. Biron, M. E. Bianchi, H. Wang and W. M. Chu: A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood, 110, 1970-81 (2007). (Pubitemid 47443911)
61. E. Latz, A. Schoenemeyer, A. Visintin, K. A. Fitzgerald, B. G. Monks, C. F. Knetter, E. Lien, N. J. Nilsen, T. Espevik and D. T. Golenbock: TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol, 5, 190-8 (2004). (Pubitemid 38208361)
62. S. E. Ewald, B. L. Lee, L. Lau, K. E. Wickliffe, G. P. Shi, H. A. Chapman and G. M. Barton: The ectodomain of Tolllike receptor 9 is cleaved to generate a functional receptor. Nature, 456, 658-62 (2008).
63. H. Hacker, R. M. Vabulas, O. Takeuchi, K. Hoshino, S. Akira and H. Wagner: Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med, 192, 595-600 (2000). (Pubitemid 30666261)
64. E. Latz, A. Verma, A. Visintin, M. Gong, C. M. Sirois, D. C. Klein, B. G. Monks, C. J. McKnight, M. S. Lamphier, W. P. Duprex, T. Espevik and D. T. Golenbock: Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol, 8, 772-9 (2007). (Pubitemid 46965353)
65. S. L. Peng: Signaling in B cells via Toll-like receptors. Curr Opin Immunol, 17, 230-6 (2005). (Pubitemid 40692656)
66. F. Takeshita, I. Gursel, K. J. Ishii, K. Suzuki, M. Gursel and D. M. Klinman: Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol, 16, 17-22 (2004). (Pubitemid 38147429)
67. G. Hartmann and A. M. Krieg: Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol, 164, 944-53 (2000).
68. A. K. Yi, J. G. Yoon and A. M. Krieg: Convergence of CpG DNA- and BCR-mediated signals at the c-Jun N-terminal kinase and NF-kappaB activation pathways: regulation by mitogen-activated protein kinases. Int Immunol, 15, 577-91 (2003). (Pubitemid 36519396)
69. A. Prakash, E. Smith, C. K. Lee and D. E. Levy: Tissuespecific positive feedback requirements for production of type I interferon following virus infection. J Biol Chem, 280, 18651-7 (2005). (Pubitemid 41379565)
70. J. A. Hanten, J. P. Vasilakos, C. L. Riter, L. Neys, K. E. Lipson, S. S. Alkan and W. Birmachu: Comparison of human B cell activation by TLR7 and TLR9 agonists. BMC Immunol, 9, 39 (2008).
71. L. Giordani, M. Sanchez, I. Libri, M. G. Quaranta, B. Mattioli and M. Viora: IFN-alpha amplifies human naive B cell TLR-9-mediated activation and Ig production. J Leukoc Biol, 86, 261-71 (2009).
72. S. Agrawal and S. Gupta: TLR1/2, TLR7, and TLR9 Signals Directly Activate Human Peripheral Blood Naive and Memory B Cell Subsets to Produce Cytokines, Chemokines, and Hematopoietic Growth Factors. J Clin Immunol, 31, 89-9 (2011).
73. A. Assaf, H. Esteves, S. J. Curnow and M. J. Browning: A threshold level of TLR9 mRNA predicts cellular responsiveness to CpG-ODN in haematological and nonhaematological tumour cell lines. Cell Immunol, 259, 90-9 (2009).
74. F. Cognasse, H. Hamzeh-Cognasse, S. Lafarge, P. Chavarin, B. Pozzetto, Y. Richard and O. Garraud: Identification of two subpopulations of purified human blood B cells, CD27- CD23+ and CD27high CD80+, that strongly express cell surface Toll-like receptor 9 and secrete high levels of interleukin-6. Immunology, 125, 430- 7 (2008).
75. F. Gantner, P. Hermann, K. Nakashima, S. Matsukawa, K. Sakai and K. B. Bacon: CD40-dependent and - independent activation of human tonsil B cells by CpG oligodeoxynucleotides. Eur J Immunol, 33, 1576-85 (2003). (Pubitemid 36790418)
76. W. Jiang, M. M. Lederman, C. V. Harding, B. Rodriguez, R. J. Mohner and S. F. Sieg: TLR9 stimulation drives naive B cells to proliferate and to attain enhanced antigen presenting function. Eur J Immunol, 37, 2205-13 (2007). (Pubitemid 47250213)
77. P. S. Espino, B. Drobic, K. L. Dunn and J. R. Davie: Histone modifications as a platform for cancer therapy. J Cell Biochem, 94, 1088-102 (2005). (Pubitemid 41420232)
78. I. Albrecht, T. Tapmeier, S. Zimmermann, M. Frey, K. Heeg and A. Dalpke: Toll-like receptors differentially induce nucleosome remodelling at the IL-12p40 promoter. EMBO Rep, 5, 172-7 (2004). (Pubitemid 38401197)
79. A. S. Weinmann, D. M. Mitchell, S. Sanjabi, M. N. Bradley, A. Hoffmann, H. C. Liou and S. T. Smale: Nucleosome remodeling at the IL-12 p40 promoter is a TLR-dependent, Rel-independent event. Nat Immunol, 2, 51-7 (2001). (Pubitemid 33704953)
80. S. L. Foster, D. C. Hargreaves and R. Medzhitov: Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature, 447, 972-8 (2007). (Pubitemid 46975746)
81. I. Tempera and P. M. Lieberman: Chromatin organization of gammaherpesvirus latent genomes. Biochim Biophys Acta, 1799, 236-45 (2010).
82. H. Bryant and P. J. Farrell: Signal Transduction and Transcription Factor Modification during Reactivation of Epstein-Barr Virus from Latency. J Virol, 76, 10290-8 (2002).
83. S. K. Pierce: Understanding B cell activation: from single molecule tracking, through Tolls, to stalking memory in malaria. Immunol Res, 43, 85-97 (2009).
84. K. S. Campbell: Signal transduction from the B cell antigen-receptor. Curr Opin Immunol, 11, 256-64 (1999). (Pubitemid 29263952)
85. T. Kurosaki: Genetic analysis of B cell antigen receptor signaling. Annu Rev Immunol, 17, 555-92 (1999). (Pubitemid 29241134)
86. S. Kreuz, D. Siegmund, J. J. Rumpf, D. Samel, M. Leverkus, O. Janssen, G. Hacker, O. Dittrich-Breiholz, M. Kracht, P. Scheurich and H. Wajant: NFkappaB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J Cell Biol, 166, 369-80 (2004). (Pubitemid 39031240)
87. J. M. Dal Porto, S. B. Gauld, K. T. Merrell, D. Mills, A. E. Pugh-Bernard and J. Cambier: B cell antigen receptor signaling 101. Mol Immunol, 41, 599-613 (2004). (Pubitemid 38824617)
88. L. B. King and J. G. Monroe: Immunobiology of the immature B cell: plasticity in the B-cell antigen receptorinduced response fine tunes negative selection. Immunol Rev, 176, 86-104 (2000).
89. A. Lanzavecchia: Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu Rev Immunol, 8, 773-93 (1990). (Pubitemid 20135646)
90. S. P. Crampton, E. Voynova and S. Bolland: Innate pathways to B-cell activation and tolerance. Ann N Y Acad Sci, 1183, 58-68 (2010).
91. A. K. Yi, D. W. Peckham, R. F. Ashman and A. M. Krieg: CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. Int Immunol, 11, 2015-24 (1999). (Pubitemid 30009161)
92. A. K. Yi, P. Hornbeck, D. E. Lafrenz and A. M. Krieg: CpG DNA rescue of murine B lymphoma cells from anti- IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J Immunol, 157, 4918-25 (1996). (Pubitemid 126449568)
93. A. Chaturvedi, D. Dorward and S. K. Pierce: The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. Immunity, 28, 799-809 (2008).
94. M. Savard and J. Gosselin: Epstein-Barr virus immunossuppression of innate immunity mediated by phagocytes. Virus Res, 119(2), 134-45 (2006). (Pubitemid 43765988)
95. I. Fathallah, P. Parroche, H. Gruffat, C. Zannetti, H. Johansson, J. Yue, E. Manet, M. Tommasino, B. S. Sylla and U. A. Hasan: EBV latent membrane protein 1 is a negative regulator of TLR9. J Immunol, 185, 6439-47 (2010).
96. M. van Gent, B. D. Griffin, E. G. Berkhoff, D. van Leeuwen, I. G. Boer, M. Buisson, F. C. Hartgers, W. P. Burmeister, E. J. Wiertz and M. E. Ressing: EBV lyticphase protein BGLF5 contributes to TLR9 downregulation during productive infection. J Immunol, 186, 1694-702 (2011).
97. V. Younesi, H. Nikzamir, M. Yousefi, J. Khoshnoodi, M. Arjmand, H. Rabbani and F. Shokri: Epstein Barr virus inhibits the stimulatory effect of TLR7/8 and TLR9 agonists but not CD40 ligand in human B lymphocytes. Microbiol Immunol, 54, 534-41 (2010).
98. H. J. Martin, J. M. Lee, D. Walls and S. D. Hayward: Manipulation of the toll-like receptor 7 signaling pathway by Epstein-Barr virus. J Virol, 81, 9748-58 (2007). (Pubitemid 350067679)
99. C. R. Ruprecht and A. Lanzavecchia: Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol, 36, 810-6 (2006).
100. S. Iskra, M. Kalla, H. J. Delecluse, W. Hammerschmidt and A. Moosmann: Toll-like receptor agonists synergistically increase proliferation and activation of B cells by epstein-barr virus. J Virol, 84, 3612-23 (2010).
101. L. M. Gargano, J. C. Forrest and S. H. Speck: Signaling through Toll-like receptors induces murine gammaherpesvirus 68 reactivation in vivo. J Virol, 83, 1474-82 (2009).
102. C. L. Ku, H. von Bernuth, C. Picard, S. Y. Zhang, H. H. Chang, K. Yang, M. Chrabieh, A. C. Issekutz, C. K. Cunningham, J. Gallin, S. M. Holland, C. Roifman, S. Ehl, J. Smart, M. Tang, F. J. Barrat, O. Levy, D. McDonald, N. K. Day-Good, R. Miller, H. Takada, T. Hara, S. Al-Hajjar, A. Al-Ghonaium, D. Speert, D. Sanlaville, X. Li, F. Geissmann, E. Vivier, L. Marodi, B. Z. Garty, H. Chapel, C. Rodriguez-Gallego, X. Bossuyt, L. Abel, A. Puel and J. L. Casanova: Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4- dependent TLRs are otherwise redundant in protective immunity. J Exp Med, 204, 2407-22 (2007). (Pubitemid 47529326)
103. E. Traggiai, S. Becker, K. Subbarao, L. Kolesnikova, Y. Uematsu, M. R. Gismondo, B. R. Murphy, R. Rappuoli and A. Lanzavecchia: An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med, 10, 871-5 (2004). (Pubitemid 39070862)
104. K. Ladell, M. Dorner, L. Zauner, C. Berger, F. Zucol, M. Bernasconi, F. K. Niggli, R. F. Speck and D. Nadal: Immune activation suppresses initiation of lytic Epstein- Barr virus infection. Cell Microbiol, 9, 2055-69 (2007). (Pubitemid 47087095)
105. L. M. Coussens and Z. Werb: Inflammation and cancer. Nature, 420, 860-7 (2002). (Pubitemid 36019639)
106. F. Balkwill and L. M. Coussens: Cancer: an inflammatory link. Nature, 431, 405-6 (2004). (Pubitemid 39329565)
107. P. A. Beachy, S. S. Karhadkar and D. M. Berman: Mending and malignancy. Nature, 431, 402 (2004). (Pubitemid 39329562)
108. R. Chen, A. B. Alvero, D. A. Silasi, K. D. Steffensen and G. Mor: Cancers take their Toll-the function and regulation of Toll-like receptors in cancer cells. Oncogene, 27, 225-33 (2008).
109. A. P. Wolffe: Chromatin remodeling: why it is important in cancer. Oncogene, 20, 2988-90 (2001). (Pubitemid 32553552)